p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma

American Journal of Clinical Pathology

Volumn 126, Issue 2, 2006, Pages 266-276

  Knopp, Synne ^a,b   Nesland, Jahn M ^a,b   Tropé, Claes ^a,b   Holm, Ruth ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Human papillomavirus; p14; p16; pRB; Prognosis

Indexed keywords

GENE PRODUCT; PROTEIN P14; PROTEIN P14ARF; RETINOBLASTOMA PROTEIN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; VIRUS DETECTION; VULVA CARCINOMA; WART VIRUS; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HISTOLOGY; ISOLATION AND PURIFICATION; LYMPH NODE; METABOLISM; METASTASIS; PAPILLOMA VIRUS; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; VIROLOGY; VIRUS INFECTION; VULVA; VULVA TUMOR;

CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LYMPH NODES; LYMPHATIC METASTASIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; VULVA; VULVAR NEOPLASMS;

EID: 33746671271     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/E9E8Y9WG5QE3LK29     Document Type: Article

References (59)

1. Trimble CL, Hildesheim A, Brinton LA, et al. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol. 1996;87:59-64.
2. Toki T, Kurman RJ, Park JS, et al. Probable nonpapillomavirus etiology of squamous cell carcinoma of the vulva in older women: a clinicopathologic study using in situ hybridization and polymerase chain reaction. Int J Gynecol Pathol. 1991;10:107-125.
3. Bloss JD, Liao SY, Wilczynski SP, et al. Clinical and histologic features of vulvar carcinomas analyzed for human papillomavirus status: evidence that squamous cell carcinoma of the vulva has more than one etiology. Hum Pathol. 1991;22:711-718.
4. Brandenberger AW, Rudlinger R, Hanggi W, et al. Detection of human papillomavirus in vulvar carcinoma: a study by in situ hybridisation. Arch Gynecol Obstet. 1992;252:31-35.
5. Iwasawa A, Nieminen P, Lehtinen M, et al. Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction. Obstet Gynecol. 1997;89:81-84.
6. Lerma E, Matias-Guiu X, Lee SJ, et al. Squamous cell carcinoma of the vulva: study of ploidy, HPV, p53, and pRb. Int J Gynecol Pathol. 1999;18:191-197.
7. Pinto AP, Schlecht NF, Pintos J, et al. Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecol Oncol. 2004;92:856-865.
8. Lee YY, Wilczynski SP, Chumakov A, et al. Carcinoma of the vulva: HPV and p53 mutations. Oncogene. 1994;9:1655-1659.
9. Kurman RJ, Toki T, Schiffman MH. Basaloid and warty carcinomas of the vulva: distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol. 1993;17:133-145.
10. Hording U, Junge J, Daugaard S, et al. Vulvar squamous cell carcinoma and papillomaviruses: indications for two different etiologies. Gynecol Oncol. 1994;52:241-246.
11. Ansink AC, Krul MR, De Weger RA, et al. Human papillomavirus, lichen sclerosus, and squamous cell carcinoma of the vulva: detection and prognostic significance. Gynecol Oncol. 1994;52:180-184.
12. Monk BJ, Burger RA, Lin F, et al. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol. 1995;85:709-715.
13. Kagie MJ, Kenter GG, Tollenaar RA, et al. p53 protein overexpression is common and independent of human papillomavirus infection in squamous cell carcinoma of the vulva. Cancer. 1997;80:1228-1233.
14. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12:2245-2262.
15. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003;13:77-83.
16. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA. 1996;93:4350-4354.
17. Knopp S, Bjorge T, Nesland JM, et al. p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas. Gynecol Oncol. 2004;95:37-45.
18. Quelle DE, Cheng M, Ashmun RA, et al. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci U S A. 1997;94:669-673.
19. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2:731-737.
20. Rolfe KJ, Crow JC, Benjamin E, et al. Cyclin D1 and retinoblastoma protein in vulvar cancer and adjacent lesions. Int J Gynecol Cancer. 2001;11:381-386.
21. Chan MK, Cheung TH, Chung TK, et al. Expression of p16INK4 and retinoblastoma protein Rb in vulvar lesions of Chinese women. Gynecol Oncol. 1998;68:156-161.
22. Lerma E, Esteller M, Herman JG, et al. Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. Hum Pathol. 2002;33:1120-1125.
23. Shepherd JH. Cervical and vulvar cancer: changes in FIGO definitions of staging. Br J Obstet Gynecol. 1996;103:405-406.
24. Knopp S, Bjorge T, Nesland JM, et al. Cyclins D1, D3, E, and A in vulvar carcinoma patients. Gynecol Oncol. 2005;97:733-739.
25. Knopp S, Holm R, Bjorge T, et al. Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases. Histopathology. In press.
26. Tavassoli FA, Diehl JA. Tumors of the vulva. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2001:316-321. World Health Organization Classification of Tumours.
27. Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983;80:3812-3815.
28. Boshart M, Gissmann L, Ikenberg H, et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151-1157.
29. Holm R, Karlsen F, Nesland JM. In situ hybridization with nonisotopic probes using different detection systems. Mod Pathol. 1992;5:315-319.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Holm R, Tanum G, Karlsen F, et al. Prevalence and physical state of human papillomavirus DNA in anal carcinomas. Mod Pathol. 1994;7:449-453.
32. Biedermann K, Dandachi N, Trattner M, et al. Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue. J Clin Microbiol. 2004;42:3758-3765.
33. Engelman DE, Andrade LA, Vassallo J. Human papillomavirus infection and p53 protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma. Braz J Med Biol Res. 2003;36:1159-1165.
34. Pinto AP, Signorello LB, Crum CP, et al. Squamous cell carcinoma of the vulva in Brazil: prognostic importance of host and viral variables. Gynecol Oncol. 1999;74:61-67.
35. Kagie MJ, Kenter GG, Zomerdijk-Nooijen Y, et al. Human papillomavirus infection in squamous cell carcinoma of the vulva, in various synchronous epithelial changes and in normal vulvar skin. Gynecol Oncol. 1997;67:17883.
36. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76-79.
37. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136.
38. Mantovani F, Banks L. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene. 1999;18:3309-3315.
39. Milde-Langosch K, Albrecht K, Joram S, et al. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer. 1995;63:639-645.
40. O'Nions J, Brooks LA, Sullivan A, et al. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer. 2001;85:1551-1556.
41. Riethdorf S, Neffen EF, Cviko A, et al. p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Hum Pathol. 2004;35:1477-1483.
42. Kanao H, Enomoto T, Ueda Y, et al. Correlation between pl4(ARF)/p!6(INK4A) expression and HPV infection in uterine cervical cancer. Cancer Lett. 2004;213:31-37.
43. Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53 [letter]. Nature. 1998;395:124-125.
44. 1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol. 1998;72:975-985.
45. Zerfass K, Schulze A, Spitkovsky D, et al. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol. 1995;69:6389-6399.
46. 1 progression. Oncogene. 1994;9:2663-2674.
47. Ruesch MN, Laimins LA. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J Virol. 1997;71:5570-5578.
48. Zerfass-Thome K, Zwerschke W, Mannhardt B, et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16E7 oncoprotein. Oncogene. 1996;13:2323-2330.
49. Funk JO, Waga S, Harry J B, et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16E7 oncoprotein. Genes Dev. 1997;11:2090-2100.
50. Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 1997;11:2101-2111.
51. Chien WM, Noya F, Benedict-Hamilton HM, et al. Alternative fates of keratinocytes transduced by human papillomavirus type 18 E7 during squamous differentiation. J Virol 2002;76:2964-2972.
52. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
53. Cullen AP, Reid R, Campion M, et al. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol. 1991;65:606-612.
54. Daniel B, Mukherjee G, Seshadri L, et al. Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. J Gen Virol. 1995;76(pt 10):2589-2593.
55. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology. 1989;172:63-72.
56. Fukushima M, Yamakawa Y, Shimano S, et al. The physical state of human papillomavirus 16 DNA in cervical carcinoma and cervical intraepithelial neoplasia. Cancer. 1990;66:2155-2161.
57. Unger ER, Vernon SD, Thorns WW, et al. Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer. J Infect Dis. 1995;172:1184-1190.
58. Hernadi Z, Szarka K, Sapy T, et al. The prognostic significance of HPV-16 genome status of the lymph nodes, the integration status and p53 genotype in HPV-16 positive cervical cancer: a long term follow up. Br J Obstet Gynaecol. 2003;110:205-209.
59. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001-5014.